385 results on '"Zaritskey, Andrey"'
Search Results
2. The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report
3. Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study
4. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial
5. Impact of age and comorbidities on the efficacy of FC and FCR regimens in chronic lymphocytic leukemia
6. Shift of N-MYC Oncogene Expression in AML Patients Carrying the FLT3-ITD Mutation
7. The biological basis and clinical symptoms of CAR-T therapy-associated toxicites
8. Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet
9. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
10. Multidrug Resistance in Acute Myelogenous Leukemia: Relevance to Clinical and Laboratory Data
11. Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials
12. PF-114 in Patients Failing Prior Tyrosine Kinase-Inhibitor Therapy Including BCR::ABL1T315I
13. Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF)
14. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up
15. AML-097: Impact of Genetic Alterations and Types of Chemotherapy on Outcomes of Patients with Extramedullary Acute Myeloid Leukemia and Myeloid Sarcoma: A Single-Center Experience
16. AML-288: The Combination of Gemtuzumab Ozogamicin and Azacitidine in the Treatment of Relapsed and Refractory AML
17. Poster: AML-288: The Combination of Gemtuzumab Ozogamicin and Azacitidine in the Treatment of Relapsed and Refractory AML
18. AML-275: Non-Intensive Chemotherapy in Elderly: Low-Efficacy ICT is Too Toxic and Targeted Therapy is Optimal
19. Poster: AML-275: Non-Intensive Chemotherapy in Elderly: Low-Efficacy ICT is Too Toxic and Targeted Therapy is Optimal
20. Poster: AML-097: Impact of Genetic Alterations and Types of Chemotherapy on Outcomes of Patients with Extramedullary Acute Myeloid Leukemia and Myeloid Sarcoma: A Single-Center Experience
21. Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study
22. T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC)
23. Primary Analysis of the Tegar Study: A Phase II Study Exploring the Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab or Rituximab in Patients with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), or Waldenstrom Macroglobulinemia (WM)
24. AML-396: Development of a Relevant Cell Model for NKG2D CAR-T Efficiency Assessment
25. AML-291: MRD Level After Induction Therapy in NPM1-Mutated Patients Identifies Those at High Risk of Relapse and Defines Indications for HSCT
26. CML-366: Baseline Cytogenetic Response Level Impact on Survival of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors as Third-Line Therapy: Real-World Data in Five Russian Centers
27. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome
28. Multidrug Resistance in Acute Myelogenous Leukemia: Relevance to Clinical and Laboratory Data
29. Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure
30. Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts
31. BCR-ABL1+ AML De Novo and CBF-Leukemia at Relapse: Game of Clones
32. PF-114: A 4th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1T315I
33. Ovarian tissue cryopreservation in prepubertal patients with oncological diseases: multidisciplinary approach and outcomes
34. Aza Maintenance After Consolidation Increase RFS in Mrdve+ Low Risk AML Patients
35. Hematopoietic Recovery After Haploidentical SCT, Comparison with Results of Matched Related SCT (MRD-SCT)
36. Impact of MRD Eradication on Survival Outcomes in CLL Patients with Different IGHV Mutation Status
37. #3 Pregancy and infant outcomes after maternal exposure to rituximab
38. Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study
39. A rapid RT-PCR based method for the detection of BCR-ABL translocation
40. Ultraviolet irradiation induces multiple DNA double-strand breaks and apoptosis in normal granulocytes and chronic myeloid leukaemia blasts
41. Ovarian tissue cryopreservation in prepubertal patients with oncological diseases: multidisciplinary approach and outcomes.
42. Social Parameters Are Independent Predictors for Survival in Chronic Myeloid Leukemia
43. Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy
44. Early Reduction of WT1 Transcript Level During Induction Chemotherapy Predicts for Longer Relapse-Free and Overall Survival in De Novo Intermediate Risk Acute Myeloid Leukemia
45. Allogeneic Stem Cell Transplantation in CML Patients with History of Accelerated Phase and Blast Crisis: Comparison of Haploidentical and Matched Related Stem Cell Transplantation
46. Evaluation of Immunosuppressive Surface Molecules, Essential for Resistance to CAR T-Cells
47. VEGFR2-specific FnCAR effectively redirects the cytotoxic activity of T cells and YT NK cells
48. PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy
49. MRD Level in NPM1 Mutated and RUNX1-RUNX1T1 Positive AML Predicts RFS and Defines Indications for ASCT
50. Standard of care and direct medical costs of the treatment of chronic lymphocytic leukemia among the adult population in Ukraine, Russia, and Kazakhstan: data from the LEUKOSPECT study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.